Try our Advanced Search for more refined results

November 26, 2019

Securities and Exchange Commission v. Mimedx Group, Inc. et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. June 08, 2023

    MiMedx Execs To Pay SEC Nearly $2M To End Fraud Claims

    Two convicted former executives of skin graft biotechnology company MiMedx have agreed to pay nearly $2 million to the U.S. Securities and Exchange Commission to resolve claims they played a role in orchestrating a "pervasive, long-running fraud" that saw the company strike backroom deals with distributors to misstate millions of dollars of revenue in its public filings.

3 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login